# A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612

> **NCT01883505** · PHASE2 · COMPLETED · sponsor: **NeuroDerm Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Levodopa and carbidopa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01883505
- **Lead sponsor:** NeuroDerm Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-06
- **Primary completion:** 2015-04-26
- **Final completion:** 2015-04-26
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01883505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01883505, "A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT01883505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*